Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Autoimmune encephalitis is a rare disease, which should be differentiated from aseptic encephalitis. Possessing anti-N-methyl-D-aspartate (NMDA) receptor autoantibody is the leading cause of autoimmune encephalitis. However, it may pose a diagnostic challenge to clinicians, especially to nonpsychiatric or non-neurologic specialist, resulting in a delayed initiation of treatment. Hence, we share the case of a patient with anti-NMDA receptor encephalitis who was hospitalized in the infectious diseases ward, presenting with acute febrile illness that preceded characteristic neuropsychiatric symptoms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2022.06.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical Anti-NMDAR encephalitis presenting with pharyngeal-cervical-bibrachial weakness: A rare case report.
Neurol Sci
September 2025
Department of Neurology, JIPMER, 605006, Puducherry, India.
A case of anti-N-methyl-D-aspartate receptor encephalitis with associated ovarian teratoma in a 23-year-old female.
Radiol Case Rep
October 2025
Discipline of Neurology, Memorial University of Newfoundland, 300 Prince Phillip Drive, St. John's, NL, Canada, A1B 3V6.
Anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis is an immune-mediated disease manifesting with a complex neuropsychiatric syndrome and anti-NMDA receptor antibodies within the cerebrospinal fluid. If not treated, it can progress to hypoventilation, coma, or death. It is often misdiagnosed as drug abuse, neuroleptic malignant syndrome, primary psychiatric disorder, or viral encephalitis.
View Article and Find Full Text PDFNeurochemical and molecular characteristics of altered brain functional activity in the anti-NMDAR encephalitis.
Neurobiol Dis
August 2025
Department of Neurology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650034, China. Electronic address:
Aims: Anti-N-methyl-d-aspartate (Anti-NMDA) receptor encephalitis is characterized by widespread neural dysfunction, yet the underlying neurochemical and molecular mechanisms remain poorly understood. This study aimed to investigate whether functional alterations in anti-NMDAR encephalitis are spatially associated with neurotransmitter receptor distributions and transcriptomic profiles, to uncover their neurochemical, molecular, and cellular signatures.
Methods: A total of 25 patients diagnosed with anti-NMDA receptor encephalitis and 30 healthy controls (HCs) were recruited in this study.
Posterior Reversible Encephalopathy Syndrome: A Case Report With Contemporary Literature Review and Neuropathological Evidence From Autopsy.
Cureus
July 2025
Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center, Shreveport, USA.
Posterior reversible encephalopathy syndrome (PRES) is a neuro-radiological condition characterized by vasogenic edema in the parieto-occipital brain regions. Although typically reversible, some cases result in irreversible damage, particularly with delayed treatment. This study reviews 12 autopsy-confirmed cases and presents a novel case, emphasizing neuropathological findings that challenge the assumption of reversibility.
View Article and Find Full Text PDFAnti-NMDA receptor encephalitis following SARS-CoV-2 infection in children.
Diagn Microbiol Infect Dis
December 2025
Department of Pediatric Neurology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, No. 1617 Riyue Avenue, Chengdu City, Sichuan Province, China. Electronic address:
Background: The purpose of this study was to report the phenomenon of anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis following novel coronavirus disease 2019 (COVID-19), to minimize misdiagnoses of this as post-COVID-19 syndrome, and to promote early identification, enabling these patients to benefit from early immunotherapy.
Methods: The study included three pediatric patients with anti-NMDA receptor encephalitis following COVID-19, treated at our hospital from July to September 2023. We collected and analyzed the clinical data from these patients, including background information, clinical presentations, laboratory examination results, imaging results, electrophysiological results, treatment, and prognosis.